Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014

Chang-Min Choi; Ho Cheol Kim; Chi Young Jung; Deog Gon Cho; Jae Hyun Jeon; Jeong Eun Lee; Jin Seok Ahn; Seung Joon Kim; Yeongdae Kim; Yoo-Duk Choi; Yang-Gun Suh; Jung-Eun Kim; Boram Lee; Young-Joo Won; Young-Chul Kim

doi:10.4143/crt.2018.704

Articles

Page Path: HOME > Cancer Res Treat > Volume 51(4); 2019 > Article

Original Article Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014: Chang-Min Choi, MD, PhD^1,2, Ho Cheol Kim, MD¹, Chi Young Jung, MD, PhD³, Deog Gon Cho, MD, PhD⁴, Jae Hyun Jeon, MD⁵, Jeong Eun Lee, MD, PhD⁶, Jin Seok Ahn, MD, PhD⁷, Seung Joon Kim, MD, PhD⁸, Yeongdae Kim, MD, PhD⁹, Yoo-Duk Choi, MD, PhD¹⁰, Yang-Gun Suh, MD, PhD¹¹, Jung-Eun Kim, BS¹², Boram Lee, MS¹², Young-Joo Won, PhD¹², Young-Chul Kim, MD, PhD^13,14,; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2019;51(4):1400-1410.
DOI: https://doi.org/10.4143/crt.2018.704
Published online: February 25, 2019

¹Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

²Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

³Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea

⁴Department of Thoracic & Cardiovascular Surgery, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea

⁵Center for Lung Cancer, National Cancer Center, Goyang, Korea

⁶Division of Pulmonology, Department of Internal Medicine, Chungnam National University, Daejeon, Korea

⁷Department of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea

⁸Division of Pulmonology, Department of Internal Medicine, The Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea

⁹Department of Cardiothoracic Surgery, Pusan National University Hospital, Busan, Korea

¹⁰Department of Pathology, Chonnam National University Medical School, Gwangju, Korea

¹¹Department of Cancer Control and Population Health, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea

¹²Cancer Registration and Statistics Branch, National Cancer Center, Goyang, Korea

¹³Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea

¹⁴Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea

Correspondence: Young-Chul Kim, MD, PhD Department of Internal Medicine, Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun 58128, Korea
Tel: 82-61-379-7614 Fax: 82-61-379-7619 E-mail: kyc0923@jnu.ac.kr

*Chang-Min Choi and Ho Cheol Kim contributed equally to this work.

• Received: December 19, 2018 • Accepted: February 22, 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

12,180 Views
541 Download
52 Web of Science
49 Crossref
54 Scopus

prev next

Full Article

Download PDF

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Abstract

Purpose
The aim of this study was to investigate epidemiology, clinical characteristics and sex differences of patients with lung cancer using nationwide registry in Korea.
Materials and Methods
The Korean Association for Lung Cancer developed a registry in cooperation with the Korean Central Cancer Registry, and surveyed about 10% of lung cancer cases. For this first survey of cases diagnosed in 2014, cases were selected through a systematic sampling method.
Results
Total 2,621 lung cancer patients were surveyed, and the median patient age was 70 years. During the study period, adenocarcinoma was the most frequent histologic type, the proportion of female patients was 28.4%, and women had a better prognosis (median survival, not reached vs. 13 months; p<0.001) than did men for non-small cell lung cancer. The proportion of never-smokers was 36.4%, and never-smoking was more prevalent in women than in men (87.5 vs. 16.0%, p<0.001). Epidermal growth factor receptor (EGFR) mutations were found in 36.8% of stage IV adenocarcinoma patients, and higher in female compared to male patients (51.2 vs. 26.6%, p<0.001). In addition, patients with EGFR mutation showed better survival (median survival, 18 vs. 8 months; p<0.001) than patients without EGFR mutation in these patients.
Conclusion
This is the first survey to gather unbiased nationwide lung cancer statistics in Korea. More than one-third of lung cancer patients had no smoking history. Female had a high proportion of non-smoker, more adenocarcinoma with EGFR mutation and generally better prognosis than male.
Key words: Lung neoplasms, Epidemiology, Korea, Never-smokers, Epidermal growth factor receptor

Introduction

Lung cancer is a leading cause of cancer-related deaths worldwide, including in South Korea [1]. Although smoking is one of the most important risk factors for lung cancer, the proportion of never-smokers with lung cancer is generally higher in Asian than in Western populations [2,3]. In addition, mutations in the epidermal growth factor receptor (EGFR) gene, which could be used as a therapeutic target, are more frequent in Asian than in Western lung cancer patients [4].

The first nationwide lung cancer survey in South Korea, conducted by the Korean Academy of Tuberculosis and Respiratory Diseases in 1997 [5], found that squamous cell carcinoma was the most common histologic type. In contrast, the second nationwide lung cancer survey, conducted by the Korean Association for Lung Cancer in 2005 [6], found that adenocarcinoma was the leading histologic type and that lack of symptoms was associated with favorable outcomes.

Generally, female sex is a favorable prognostic factor for lung cancer [7,8]. However, many of these studies were performed in limited groups of patients with specific conditions, such as non-small cell lung cancer (NSCLC) alone [9], or in those treated with certain modalities [10].

To build an unbiased and informative lung cancer registry, the Korean Association for Lung Cancer (KALC) developed a registry (KALC-R) in cooperation with the Korean Central Cancer Registry (KCCR), and surveyed about 10% of lung cancer cases. This study investigated epidemiology, clinical characteristics and sex differences in Korean lung cancer patients using data from the KALC-R of the year 2014.

Materials and Methods

1. Study populations and methods

In 2014, the KCCR registered 24,253 patients newly diagnosed with lung cancer. Among these patients, several patients were excluded with KCCR selection criteria (such as excluding patients who enrolled more than one institution), the total survey population was 21,960 patients. The final survey population comprised 13 regional cancer centers and 39 hospitals from which significant number of registrations were made. Sample size in each hospital (cluster) was determined by selection probability based on the number of registration in each hospital. And patients of each hospital were sorted by date of first diagnosis, sex, age, and Surveillance, Epidemiology, and End Results program (SEER) summary stage. Two thousand six hundred forty patients were selected from each of 52 hospitals using a systematic sampling method [11]. In a process of survey, 19 patients with multiple primary cancer were excluded. In conclusion, 2,621 patients were analyzed in this paper.

A standardized protocol was used to collect data regarding patient age, sex, body mass index (BMI), smoking history, histopathologic tumor type, symptoms, performance status (PS), Eastern Corporative Oncology Group (ECOG) score, clinical stage (according to the seventh edition of the TNM International Staging System), treatment modality, results of molecular tests including EGFR mutation and anaplastic lymphoma kinase (ALK) translocation, and survival status. We defined ever-smokers those with any history of smoking prior to index lung cancer and never-smokers as those with no smoking history. Information such as BMI and PS was obtained in the initial date of visit at the time of diagnosis. Patie-nts were followed up until December 2017.

2. Statistical analysis

Continuous variables are expressed as mean±standard deviation (SD) or median (interquartile range [IQR]), and categorical variables as percentages. Continuous variables were compared using a Mann-Whitney U test, and categorical variables using chi-square or Fisher exact test, as appropriate. Risk factors for mortality were analyzed using Cox proportional hazards models. Variables with a p-value of < 0.20 on univariate analysis were used in the multivariate analysis. Survival was analyzed by the Kaplan-Meier method and compared by log-rank tests. All p-values were two-tailed, with statistical significance set at p < 0.05. All statistical analyses were performed using SPSS ver. 20.0 (IBM Corp., Armonk, NY).

3. Ethical statement

The study protocol was reviewed and approved by the Institutional Review Board at the National Cancer Center (NCC2018-0193), which waived the requirement for informed consent due to the retrospective nature of the study.

Results

1. Patient characteristics

A total of 2,621 lung cancer patients were enrolled at 52 sites in South Korea; there were no differences in sex and age category between survey population and sample (Table 1). Baseline characteristics of enrolled patients are shown in Table 2. The median patient age was 70 years (IQR, 61 to 76 years), 71.6% were men (lower than that in previous studies (79.3% in 1997 and 75.8% in 2005) and men were older than women (median age, 70 years vs. 68 years; p=0.002). Smoking history was significantly more frequent (84.0% vs. 12.5%, p < 0.001) and mean BMI was significantly lower (22.7 kg/m² vs. 23.6 kg/m², p < 0.001) in men than in women. Of all patients, 13.7% were asymptomatic at the time of diagnosis, with men being more likely to have symptoms such as cough, sputum, hoarseness, hemoptysis, and weight loss, than women. In case of histopathology, adenocarcinoma (48.4%) was the leading subtype in total patients. While adenocarcinoma was more common in woman (74.8% vs. 38.0%, p < 0.001) compared to male patients, squamous cell carcinoma and small cell carcinoma were more common in male patients.

Among patients with NSCLC, 28.4% had stage I, 8.5% had stage II, 18.1% had stage III, and 45.0% had stage IV disease. The proportion of patients with stage I NSCLC was higher in women (38.7%) than in men (23.8%), whereas the proportion of patients with stage IV tumors was similar (44.1% vs. 45.4%). Among patients with NSCLC, 37.6% of patients received surgery as the initial treatment, 29.0% were treated with chemotherapy, 8.3% received radiation therapy, and 12.8% received no specific anti-cancer treatment. Surgery was significantly more frequent in women than in men (45.5% vs. 34.1%, p < 0.001), whereas radiation therapy (5.2% vs. 9.7%, p < 0.001), concurrent chemoradiation therapy (2.6% vs. 5.0%, p=0.010), and best supportive care (9.7% vs. 14.1%, p=0.004) were significantly less frequent in women.

Among patients with small cell lung cancer (SCLC), 36.6% had limited-stage and 63.4% had extensive-stage disease. Almost 60% of SCLC patients were treated with chemotherapy as the initial treatment, 15.4% received concurrent chemoradiation therapy, and 12.9% received no specific anticancer treatment. There were no sex-associated differences in clinical staging and initial treatment modalities in patients with SCLC.

2. Patient characteristics by smoking history

Among 2,580 patients with smoking history, 939 (36.4%) were never-smokers. The comparison of characteristics between ever-smokers and never-smokers is shown in Table 3. The never-smoker group had fewer men (31.5% vs. 94.4%, p < 0.001), and showed higher BMI (23.4 kg/m² vs. 22.6 kg/m², p < 0.001) compared with the ever-smoker group. In addition, the never-smoker group included more asymptomatic patients (16.7% vs. 12.2%, p=0.001), and had better PS than did the ever-smoker group (p=0.045). Among patients with NSCLC, the incidence of stage I disease was higher in never-smokers (36.8%) than in ever-smokers (23.3%), whereas that of stage IV disease was similar (45.5% vs. 44.2%). Among patients with SCLC, never-smokers had more extensive-stage disease than did ever-smokers (75.9% vs. 60.8%, p=0.030).

Clinicopathologic characteristics of patients classified by sex and smoking habits are shown in Table 4. Of the 2,580 patients with available smoking history, 43.3% smoked over 30 pack-years, 20.3% smoked less than 30 pack-years, and 36.4% were never-smokers. The proportions of women in these three groups were 2.8%, 11.6%, and 68.5%, respectively. There were no sex-associated differences in clinicopathologic characteristics of patients who ever-smoked. However, assessments of never-smokers showed that women were younger (median, 68 years vs. 71 years; p=0.003), were more likely to have adenocarcinoma histology (79.9% vs. 56.1%), and had an earlier NSCLC clinical stage than did men.

3. Prognostic factor and survival analysis

The 2,265 NSCLC patients were followed up for a median of 17 months (IQR, 5 to 32 months), during which 1,321 patients (58.3%) died. Univariate Cox analysis showed that old age, male sex, ever-smoker status, low BMI, poor PS, higher clinical stage, squamous cell carcinoma histology (compared with adenocarcinoma), and non-surgical therapy or best supportive care (compared with surgery) were significant predictors of mortality. On multivariate Cox analysis, these clinical variables, except for ever-smoker and squamous cell carcinoma histology, remained significant prognostic factors (Table 5). Among NSCLC patients, median survival was significantly longer for women than for men (not reached vs. 13 months, p < 0.001) (Fig. 1A) and survival significantly differed with clinical stage at diagnosis (Fig. 1B).

The 356 SCLC patients were followed up for a median of 8 months (IQR, 2 to 16 months), during which 306 patients (86.0%) died. Univariate and multivariate Cox analyses showed that older age, lower BMI, poor PS, extensive stage, and best supportive care were significant predictors of mortality (Table 6). Although ever-smoker seemed to be a favorable prognostic factor on univariate analysis, ever-smokers were younger and tended to have a more limited stage than did never-smokers (S1 Table). Although median survival was similar in men and women with SCLC (8 months vs. 8 months, p=0.785) (Fig. 1C), survival significantly differed with clinical stage at diagnosis (Fig. 1D).

4. Molecular profile and survival analysis among patients with adenocarcinoma in the year 2014

Of the 571 patients diagnosed with stage IV adenocarcinoma, 339 (59.4%) were men (Table 7). EGFR mutations were analyzed in 496 (86.9%) patients, and 182 patients (36.8%) had mutations. Although mutation frequency was significantly higher in women than in men (51.2% vs. 26.6%, p < 0.001), the proportion of mutation-positive men and women treated with a targeted agent did not differ. ALK translocation was analyzed in 109 patients and 15 patients (13.8%) showed ALK translocation. Although translocation frequency was not different among women and men (15.7% vs. 12.1%, p=0.584), the proportion treated with a targeted agent was higher in women than in men (75.0% vs. 14.3%, p=0.041).

Patients with stage IV adenocarcinoma were followed up for a median of 10 months (IQR, 3 to 23 months), during which 437 patients (76.5%) died. On univariate Cox analysis, older age, male sex, ever-smoker status, lower BMI, and poor PS were associated with mortality, and target driver mutation (EGFR mutation and/or ALK translocation) was associated with a favorable outcome. On multivariate Cox analysis, old age, low BMI, poor PS, and target driver mutation remained significant independent predictors of mortality (S2 Table). Women had improved survival (median 15 vs. 8 months, p < 0.001) (Fig. 2A) compared to men in patients with stage IV adenocarcinoma. In addition, patients who harbored EGFR mutations showed better prognosis (18 months vs. 8 months, p < 0.001) (Fig. 2B) than did patients without EGFR mutations. Among patients with stage IV adenocarcinoma and EGFR mutations, patients treated with a target agent showed better prognosis (21 months vs. 13 months, p=0.027) than those who were not treated.

Discussion

Relative to patients of other ethnicities, Asians with lung cancer have generally been reported to have a lower prevalence of smoking and a higher prevalence of tumor-associated EGFR mutations; these factors may be responsible for the more favorable prognosis in Asians [12]. Our nationwide survey, showing the clinical characteristics of lung cancer in South Korea, yielded results comparable to those in other studies of Asian patients. In contrast to prior nationwide surveys in Korea, which was conducted by academic societies, this is the first unbiased statistic data of Korean nationwide lung cancer survey.

Unbiased and reliable epidemiological data are important to identify time trends in diseases and to establish government policy. Although two previous nationwide surveys were performed in South Korea, potential selection bias could not be ruled out during registration of cases at the individual hospital level. Since all patients with confirmed disease codes of C34 are registered in the KCCR, KCCR data have the advantage of including nearly all lung cancer patients without selection bias. The KALC and KCCR have formulated a lung cancer-specific registration system (KALC-R), which has about 80 data fields for demographic data, symptoms, smoking history, histological findings, staging data, molecular study results, and initial treatment details [13]. Recently, our group reported on a pilot survey of 489 patients diagnosed with lung cancer in 2013 [14]; the demographic characteristics were comparable with those from other studies based on the nationwide registry [15,16]. In the current study, among 24,253 newly diagnosed lung cancer patients, about 10% were surveyed from 52 hospitals by a systematic sampling method, which helped eliminate potential bias in sample selection.

The epidemiology of lung cancer in South Korea have changed over time, major recent changes in epidemiology are summarized in S3 Fig. Compared to previous registry-based studies, the incidence of adenocarcinoma increased over the study period in both men and women. In 1997, although the most frequent histological type was squamous cell carcinoma (44.7%), adenocarcinoma incidence has increased over time, and has been the most incident histologic type since 2005. This observation may be explained by changes in cigarette components as well as by risk factors not related to smoking such as occupational risk and air pollution [17]. In addition to changes in histologic type prevalence, the development of screening methods such as low-dose chest computed tomography have led to an increased incidence of asymptomatic, early, and peripherally located cancers [18]. Thus, percutaneous lung biopsy has been most commonly performed for tissue confirmation. Additionally, the frequent use of positron emission tomography with computed tomography (PET-CT) has resulted in increased proportions of patients with stage IV lung cancer. Moreover, the use of PET-CT has made evaluation and characterization of the mediastinal lymph node more feasible; the endobronchial ultrasound-guided transbronchial needle aspiration has gained popularity and is an important diagnostic tool, especially in clinically evident N2 NSCLC [19].

Although smoking is one of the most important causes of lung cancer, the prevalence of cigarette smoking is decreasing in Korea, according to the Korea National Health and Nutrition Examination Survey [20]. In addition, the magnitude of the effect of smoking on lung cancer is smaller in Asian than in Western populations, a phenomenon termed the smoking paradox [21]. Asians are generally older at smoking initiation than are Westerners, and prefer less toxic or filtered tobacco. In contrast, the incidence of lung cancer among never-smokers is higher in Asian populations [2]. Genetic differences such as higher EGFR gene mutation rates in Asian populations and poor ventilation combined with the use of coal may explain these findings [22]. Indeed, about 87.5% of women patients in this survey had no smoking history. Additional studies are required to determine the potential risk factors for lung cancer in never-smokers.

Compared with previous registry-based studies, the incidence of lung cancer in women was higher in this study. Among patients with NSCLC, women had more favorable outcomes than did men, in agreement with previous studies showing better survival outcomes in women than in men with lung cancer [9,23]. Generally, women are diagnosed with lung cancer at a younger age and include a higher percentage of non-smokers, and both these factors are associated with more favorable outcomes. These differences may partly be due to differences in genetic background and hormonal status [24], which affect susceptibility to carcinogens. In addition, because women are more likely to have adenocarcinoma primarily located peripherally [25], the impact of early diagnosis on survival may be greater in women than in men. EGFR mutations are more frequent in women than in men [26], which may contribute to survival advantages. Treatment with targeted agents has been associated with favorable outcomes in patients positive for EGFR mutations and may contribute to the sex differences in survival [27]. However, sex was not associated with survival in patients with SCLC, in contrast to findings from studies in Western populations [28,29]. Among the 356 SCLC patients, only 53 (14.9%) were women. Although sex was not a prognostic factor with statistical significance in this small group of SCLC patients, additional studies in larger populations are needed to confirm this finding.

Among patients with stage IV adenocarcinoma and tested for EGFR mutation, 36.8% were positive for EGFR mutations. EGFR mutations were more common in women than in men, similar to the findings of previous studies in Asian populations [4]. Generally, compared to Western populations, Asians show higher EGFR mutation rates; this may contribute to the more favorable clinical outcomes observed in Asians [30]. The present study found that target driver mutations including EGFR mutations were significant prognostic factors, even after adjusting for other clinical variables. Although EGFR tyrosine kinase inhibitors have shown efficacy [27], EGFR mutation tests were not performed in all of our patients, though it is possible that test data were not provided during this survey for some cases. However, physicians should be aware of the need to test for EGFR mutations in all patients with advanced adenocarcinoma.

This study had several limitations. First, the retrospective study design resulted in an unavoidable deficiency of information such as second-hand smoking status and risk factors other than smoking. However, the strength of the study lies in the unbiased sampling method used to sample a representative population of patients with lung cancer. Second, disease-free survival and progression-free survival rates, as well as complete treatment modalities, could not be analyzed. However, overall survival rate is an acceptable, clear-cut, and important primary outcome. Finally, although the number of patients in this study was relatively large, it was not adequate to perform meaningful comparisons within subgroups with specific conditions. However, we believe that the present study will help in understanding the current trends in the epidemiology of lung cancer and may serve as a reference for future studies.

In conclusion, the evaluation of this unbiased nationwide survey dataset revealed female had a high proportion of non-smoker, more adenocarcinoma with EGFR mutation and generally better prognosis than male. And more than one-third of lung cancer patients had no smoking history. The results of this study show that the development of more effective early lung cancer screening and health insurance programs for lung cancer are indicated.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).

S1 Table.

Baseline characteristics of small cell lung cancer (SCLC) patients according to smoking history

crt-2018-704-suppl1.pdf

S2 Table.

Risk factors for mortality in patients with stage IV adenocarcinoma assessed using Cox proportional hazards models

crt-2018-704-suppl2.pdf

S3 Fig.

Nationwide trends in the epidemiology of lung cancer in South Korea.

crt-2018-704-suppl3.pdf

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

This study was supported by the Health Promotion Fund, Ministry of Health & Welfare, Republic of Korea (1660680). The data used for this study were provided by the KALC and the Ministry of Health and Welfare, KCCR.

Fig. 1.

Overall survival in patients with non-small cell lung cancer, according to sex (A) and clinical stage (B). Overall survival in patients with small cell lung cancer, according to sex (C) and clinical stage (D).

Fig. 2.

Overall survival in patients with stage IV adenocarcinoma, according to sex (A) and epidermal growth factor receptor (EGFR) mutation (B).

Table 1.

Comparison of sex and age category between survey population and sample

	Survey population	Sample	p-value
No. of patients	21,960	2,621
Male sex	15,500 (70.6)	1,876 (71.6)	0.291
Age category (yr) (total patients)
< 40	245 (1.1)	29 (1.1)	0.524
40-50	926 (4.2)	121 (4.6)
50-60	3,416 (15.6)	424 (16.2)
60-70	5,996 (27.3)	734 (28.0)
≥ 70	11,377 (51.8)	1,313 (50.1)
Age category (yr) (male patient)
< 40	119 (0.8)	15 (0.8)	0.563
40-50	511 (3.3)	72 (3.8)
50-60	2,204 (14.2)	283 (15.1)
60-70	4,487 (29.0)	542 (28.9)
≥ 70	8,179 (52.8)	964 (51.4)
Age category (yr) (female patient)
< 40	126 (2.0)	14 (1.9)	0.617
40-50	415 (6.4)	49 (6.6)
50-60	1,212 (18.8)	141 (18.9)
60-70	1,509 (23.4)	192 (25.8)
≥ 70	3,198 (49.5)	349 (46.9)

Values are presented as number (%).

Table 2.

Baseline characteristics of study patients in the year 2014

	Total	Men	Women	p-value
No. of patients	2,621	1,876 (71.6)	745 (28.4)
Age (yr)	70 (61-76)	70 (62-76)	68 (58-75)	0.002
Ever-smoker (n=2,580)	1,641 (63.6)	1,549 (84.0)	92 (12.5)	< 0.001
BMI (kg/m²)	22.9±3.6	22.7±3.5	23.6±3.7	< 0.001
Symptoms
Asymptomatic	360 (13.7)	239 (12.7)	121 (16.2)	0.019
Cough	922 (35.2)	689 (36.7)	233 (31.3)	0.008
Sputum	564 (21.5)	446 (23.8)	118 (15.8)	< 0.001
Dyspnea	534 (20.4)	380 (20.3)	154 (20.7)	0.812
Hoarseness	46 (1.8)	40 (2.1)	6 (0.8)	0.020
Hemoptysis	157 (6.0)	139 (7.4)	18 (2.4)	< 0.001
Weight loss	168 (6.4)	136 (7.2)	32 (4.3)	0.005
Pain	512 (19.5)	369 (19.7)	143 (19.2)	0.782
Histopathology
Adenocarcinoma	1,269 (48.4)	712 (38.0)	557 (74.8)	< 0.001
Squamous cell carcinoma	654 (25.0)	597 (31.8)	57 (7.7)	< 0.001
Small cell carcinoma	356 (13.6)	303 (16.2)	53 (7.1)	< 0.001
Others	354 (13.5)	272 (14.5)	82 (11.0)	0.019
Performance status (n=1,873)
0-1	1,756 (93.8)	1,235 (93.2)	521 (95.1)	0.129
2-4	117 (6.2)	90 (6.8)	27 (4.9)
Clinical stage of NSCLC (n=2,234)
I	634 (28.4)	369 (23.8)	265 (38.7)	< 0.001
II	190 (8.5)	146 (9.4)	44 (6.4)
III	405 (18.1)	331 (21.4)	74 (10.8)
IV	1,005 (45.0)	703 (45.4)	302 (44.1)
Initial treatment of NSCLC (n=2,265)
Surgery	851 (37.6)	536 (34.1)	315 (45.5)	< 0.001
Surgery only	563 (66.2)	343 (64.0)	220 (69.8)
Surgery and adjuvant therapy	288 (33.8)	193 (36.0)	95 (30.2)
RT only	188 (8.3)	152 (9.7)	36 (5.2)	< 0.001
CCRT	96 (4.2)	78 (5.0)	18 (2.6)	0.010
Chemotherapy	657 (29.0)	456 (29.0)	201 (29.0)	0.978
Best supportive care	289 (12.8)	222 (14.1)	67 (9.7)	0.004
Unknown	184 (8.1)	129 (8.2)	55 (7.9)	0.839
Clinical stage of SCLC (n=350)
Limited stage	128 (36.6)	109 (36.7)	19 (35.8)	0.906
Extensive stage	222 (63.4)	188 (63.3)	34 (64.2)
Initial treatment of SCLC (n=356)
Surgery	10 (2.8)	9 (3.0)	1 (1.9)	1.000
RT only	17 (4.8)	14 (4.6)	3 (5.7)	0.727
CCRT	55 (15.4)	46 (15.2)	9 (17.0)	0.738
Chemotherapy	213 (59.8)	186 (61.4)	27 (50.9)	0.153
Best supportive care	46 (12.9)	36 (11.9)	10 (18.9)	0.162
Unknown	15 (4.2)	12 (4.0)	3 (5.7)	0.570

Values are presented as median (interquartile range), number (%), or mean±standard deviation. BMI, body mass index; NSCLC, non-small cell lung cancer; RT, radiation therapy; CCRT, concurrent chemoradiation therapy; SCLC, small cell lung cancer.

Table 3.

Comparison of characteristics between ever-smoker and never-smoker participants

	Total	Ever-smoker	Never-smoker	p-value
No. of patients	2,580	1,641 (63.6)	939 (36.4)
Male sex	1,845 (71.5)	1,549 (94.4)	296 (31.5)	< 0.001
Age (yr)	69 (61-76)	70 (62-76)	69 (59-76)	0.055
BMI (kg/m²)	22.9±3.5	22.6±3.5	23.4±3.6	< 0.001
Symptoms
Asymptomatic	357 (13.8)	200 (12.2)	157 (16.7)	0.001
Cough	913 (35.4)	630 (38.4)	283 (30.1)	< 0.001
Sputum	557 (21.6)	407 (24.8)	150 (16.0)	< 0.001
Dyspnea	527 (20.4)	358 (21.8)	169 (18.0)	0.021
Hoarseness	46 (1.8)	37 (2.3)	9 (1.0)	0.017
Hemoptysis	156 (6.0)	129 (7.9)	27 (2.9)	< 0.001
Weight loss	167 (6.5)	128 (7.8)	39 (4.2)	< 0.001
Pain	508 (19.7)	326 (19.9)	182 (19.4)	0.766
Performance status (n=1,857)
0-1	1,743 (93.9)	1,091 (93.0)	652 (95.3)	0.045
2-4	114 (6.1)	82 (7.0)	32 (4.7)
Clinical stage of NSCLC (n=2,201)
I	631 (28.7)	311 (23.3)	320 (36.8)	< 0.001
II	187 (8.5)	127 (9.5)	60 (6.9)
III	399 (18.1)	305 (22.9)	94 (10.8)
IV	984 (44.7)	589 (44.2)	395 (45.5)
Clinical stage of SCLC (n=344)
Limited stage	126 (36.6)	112 (39.2)	14 (24.1)	0.030
Extensive stage	218 (63.4)	174 (60.8)	44 (75.9)

Values are presented as number (%), median (interquartile range), or mean±standard deviation. BMI, body mass index; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.

Table 4.

Clinicopathologic characteristics of patients according to smoking frequency, stratified by sex (total=2,580)

	Ever-smoker (≥ 30 pack years, n=1,116, 43.3%)			Ever-smoker (< 30 pack years, n=525, 20.3%)			Never-smoker (n=939, 36.4%)
	Men	Women	p-value	Men	Women	p-value	Men	Women	p-value
No. of patients	1,085 (97.2)	31 (2.8)		464 (88.4)	61 (11.6)		296 (31.5)	643 (68.5)
Age (yr)	70 (63-75)	71 (64-82)	0.378	70 (59-76)	68 (58-78)	0.817	71 (63-77)	68 (58-75)	0.003
Age category (yr)
0-50	19 (1.8)	2 (6.5)	0.027	48 (10.3)	6 (9.8)	0.816	20 (6.8)	55 (8.6)	0.086
50-60	169 (15.6)	3 (9.7)		74 (15.9)	12 (19.7)		38 (12.8)	125 (19.4)
60-70	342 (31.5)	10 (32.3)		110 (23.7)	13 (21.3)		82 (27.7)	168 (26.1)
70-80	431 (39.7)	8 (25.8)		167 (36.0)	19 (31.1)		115 (38.9)	221 (34.4)
≥ 80	124 (11.4)	8 (25.8)		65 (14.0)	11 (18.0)		41 (13.9)	74 (11.5)
Performance status
0-1	727 (67.0)	18 (58.1)	0.106	302 (65.1)	44 (72.1)	0.356	194 (65.5)	464 (71.2)	0.172
2-4	51 (4.7)	4 (12.9)		23 (5.0)	4 (6.6)		13 (4.4)	19 (3.0)
Unknown	306 (28.3)	9 (29.0)		139 (30.0)	13 (21.3)		89 (30.1)	166 (25.8)
Histology
Adenocarcinoma	329 (30.3)	7 (22.6)	0.349	204 (44.4)	29 (47.5)	0.109	166 (56.1)	514 (79.9)	< 0.001
Squamous cell carcinoma	387 (35.7)	11 (35.5)		134 (28.9)	16 (26.2)		64 (21.6)	27 (4.2)
Small cell lung cancer	216 (19.9)	10 (32.3)		54 (11.6)	12 (19.7)		28 (9.5)	30 (4.7)
Others	153 (14.1)	3 (9.7)		72 (15.5)	4 (6.6)		38 (12.8)	72 (11.2)
NSCLC stage
I	189 (21.7)	7 (33.3)	0.752	103 (25.1)	12 (24.5)	0.698	75 (28.0)	245 (40.0)	0.006
II	98 (11.3)	2 (9.5)		23 (5.6)	4 (8.2)		22 (8.2)	38 (6.2)
III	213 (24.5)	4 (19.0)		76 (18.5)	12 (24.5)		36 (13.4)	58 (9.5)
IV	356 (41.0)	8 (38.1)		204 (49.8)	21 (42.9)		129 (48.1)	266 (43.4)
Unknown	13 (1.5)	0		4 (1.0)	0		6 (2.2)	6 (1.0)
SCLC
Limited	87 (40.3)	4 (40.0)	0.908	14 (25.9)	7 (58.3)	0.085	7 (25.0)	7 (23.3)	0.882
Extensive	125 (57.9)	6 (60.0)		38 (70.4)	5 (41.7)		21 (75.0)	23 (76.7)
Unknown	4 (1.9)	0		2 (3.7)	0		0	0

Values are presented as number (%) or median (interquartile range). NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.

Table 5.

Risk factors for mortality in patients with NSCLC assessed by Cox proportional hazards model

	Univariate analysis			Multivariate analysis
	Hazard ratio	95% CI	p-value	Hazard ratio	95% CI	p-value
Age	1.036	1.028-1.043	< 0.001	1.020	1.012-1.028	< 0.001
Male sex	2.112	1.788-2.494	< 0.001	1.704	1.326-2.182	< 0.001
Ever-smoker	1.772	1.572-2.056	< 0.001	1.038	0.829-1.298	0.747
BMI	0.895	0.876-0.915	< 0.001	0.954	0.930-0.979	< 0.001
Performance status
0-1 (ref)	1.000			1.000
2-4	3.166	2.453-4.085	< 0.001	1.410	1.012-1.964	0.042
Clinical stage
I (ref)	1.000			1.000
II	3.539	2.406-5.203	< 0.001	2.494	1.602-3.881	< 0.001
III	7.946	5.883-10.734	< 0.001	4.141	2.854-6.007	< 0.001
IV	13.634	10.330-17.994	< 0.001	6.972	4.861-9.999	< 0.001
Histology
Adenocarcinoma (ref)	1.000			1.000
Squamous cell carcinoma	1.833	1.575-2.133	< 0.001	1.187	0.994-1.430	0.053
Treatment
Surgery (ref)	1.000			1.000
Non-surgical treatment	6.516	5.364-7.916	< 0.001	2.214	1.711-2.864	< 0.001
Best supportive care	15.733	12.044-20.552	< 0.001	4.954	3.495-7.021	< 0.001

NSCLC, non-small cell lung cancer; CI, confidence interval; BMI, body mass index.

Table 6.

Risk factors for mortality in patients with small cell lung cancer assessed using Cox proportional hazards models

	Univariate analysis			Multivariate analysis
	Hazard ratio	95% CI	p-value	Hazard ratio	95% CI	p-value
Age	1.042	1.028-1.057	< 0.001	1.036	1.019-1.054	< 0.001
Male sex	1.045	0.754-1.448	0.793
Ever-smoker	0.705	0.518-0.959	0.026	0.867	0.588-1.280	0.473
BMI	0.910	0.877-0.945	< 0.001	0.938	0.901-0.977	0.002
Performance status
0-1 (ref)	1.000			1.000
2-4	3.106	1.947-4.955	< 0.001	2.436	1.379-4.305	0.002
Clinical stage
Limited (ref)	1.000			1.000
Extensive	2.262	1.762-2.903	< 0.001	2.331	1.719-3.160	< 0.001
Treatment
Anti-cancer treatment (ref)	1.000			1.000
Best supportive care	4.925	3.514-6.904	< 0.001	2.173	1.320-3.576	0.002

CI, confidence interval; BMI, body mass index.

Table 7.

Characteristics of patients with stage IV adenocarcinoma

	Total	Men	Women	p-value
No. of patients	571	339 (59.4)	232 (40.6)
Age (yr)	68 (58-76)	67 (58-74)	70 (57-76)	0.168
Ever-smoker(n=561)	272 (48.5)	255 (76.3)	17 (7.5)	< 0.001
BMI (kg/m²)	22.6±3.3	22.4±3.3	22.9±3.3	0.060
Performance status (n=414)
0-1	386 (93.2)	227 (92.3)	159 (94.6)	0.346
2-4	28 (6.8)	19 (7.7)	9 (5.4)
EGFR mutation status (n=496)
Positive	182 (36.8)	77 (26.6)	105 (51.2)	< 0.001
Negative	313 (63.2)	213 (73.4)	100 (48.8)
EGFR target agent usage
Yes	122 (67.0)	48 (62.3)	74 (70.5)	0.249
No	60 (33.0)	29 (37.7)	31 (29.5)
ALK translocation status (n=109)
Positive	15 (13.8)	7 (12.1)	8 (15.7)	0.584
Negative	94 (86.2)	51 (87.9)	43 (84.3)
ALK target agent usage
Yes	7 (46.7)	1 (14.3)	6 (75.0)	0.041
No	8 (53.3)	6 (85.7)	2 (25.0)

Values are presented as median (interquartile range), number (%), or mean±standard deviation. BMI, body mass index; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.

REFERENCES

1. Jung KW, Won YJ, Kong HJ, Lee ES; Community of Population-Based Regional Cancer Registries. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat. 2018;50:303–16. Article PubMed PMC PDF
2. Cho J, Choi SM, Lee J, Lee CH, Lee SM, Kim DW, et al. Proportion and clinical features of never-smokers with non-small cell lung cancer. Chin J Cancer. 2017;36:20.Article PubMed PMC PDF
3. Wakelee HA, Chang ET, Gomez SL, Keegan TH, Feskanich D, Clarke CA, et al. Lung cancer incidence in never smokers. J Clin Oncol. 2007;25:472–8. Article PubMed PMC
4. Yatabe Y, Kerr KM, Utomo A, Rajadurai P, Tran VK, Du X, et al. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. J Thorac Oncol. 2015;10:438–45. Article PubMed PMC
5. Lee C, Kang KH, Koh Y, Chang J, Chung HS, Park SK, et al. Characteristics of lung cancer in Korea, 1997. Lung Cancer. 2000;30:15–22. Article PubMed
6. In KH, Kwon YS, Oh IJ, Kim KS, Jung MH, Lee KH, et al. Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: a Korean Lung Cancer Registry Study. Lung Cancer. 2009;64:232–7. Article PubMed
7. Ferguson MK, Skosey C, Hoffman PC, Golomb HM. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol. 1990;8:1402–7. Article PubMed
8. Visbal AL, Williams BA, Nichols FC 3rd, Marks RS, Jett JR, Aubry MC, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg. 2004;78:209–15. Article PubMed
9. Sakurai H, Asamura H, Goya T, Eguchi K, Nakanishi Y, Sawabata N, et al. Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study. J Thorac Oncol. 2010;5:1594–601. Article PubMed
10. Minami H, Yoshimura M, Miyamoto Y, Matsuoka H, Tsubota N. Lung cancer in women: sex-associated differences in survival of patients undergoing resection for lung cancer. Chest. 2000;118:1603–9. Article PubMed
11. Black K. Business statistics for contemporary decision making. Hoboken, NJ: John Wiley & Sons Inc.; 2004.
12. Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2006;24:2158–63. Article PubMed
13. Kim YC, Won YJ. The development of the Korean Lung Cancer Registry (KALC-R). Tuberc Respir Dis. 2019;82:91–3. Article
14. Kim HC, Jung CY, Cho DG, Jeon JH, Lee JE, Ahn JS, et al. Clinical characteristics and prognostic factors of lung cancer in Korea: a pilot study of data from the Korean Nationwide Lung Cancer Registry. Tuberc Respir Dis. 2019;82:118–25. Article
15. Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2010;5:29–33. Article PubMed
16. Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol. 2016;11:1653–71. Article PubMed PMC
17. Samet JM, Avila-Tang E, Boffetta P, Hannan LM, OlivoMarston S, Thun MJ, et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res. 2009;15:5626–45. Article PubMed PMC
18. National Lung Screening Trial Research Team; Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368:1980–91. Article PubMed PMC
19. Yoon HY, Lee JC, Kim SW, Kim HR, Kim YH, Choi SH, et al. Prognosis of multi-level N2-positive non-small cell lung cancer according to lymph node staging using endobronchial ultrasound-transbronchial biopsy. Thorac Cancer. 2018;9:684–92. Article PubMed PMC
20. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44:1428–46. Article PubMed
21. Jung KJ, Jeon C, Jee SH. The effect of smoking on lung cancer: ethnic differences and the smoking paradox. Epidemiol Health. 2016;38:e2016060Article PubMed PMC PDF
22. Saito M, Shiraishi K, Kunitoh H, Takenoshita S, Yokota J, Kohno T. Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci. 2016;107:713–20. Article PubMed PMC
23. Pauk N, Kubik A, Zatloukal P, Krepela E. Lung cancer in women. Lung Cancer. 2005;48:1–9. Article PubMed
24. Shriver SP, Bourdeau HA, Gubish CT, Tirpak DL, Davis AL, Luketich JD, et al. Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J Natl Cancer Inst. 2000;92:24–33. Article PubMed
25. Sone S, Takashima S, Li F, Yang Z, Honda T, Maruyama Y, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet. 1998;351:1242–5. Article PubMed
26. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339–46. Article PubMed PDF
27. Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol. 2008;26:5589–95. Article PubMed
28. Johnson BE, Steinberg SM, Phelps R, Edison M, Veach SR, Ihde DC. Female patients with small cell lung cancer live longer than male patients. Am J Med. 1988;85:194–6. Article PubMed
29. Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res. 1986;46:4189–94. PubMed
30. Ahn MJ, Lee J, Park YH, Ahn JS, Ziogas A, Zell JA, et al. Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era. J Thorac Oncol. 2010;5:1185–96. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Prognostic value of electronic health records-based frailty measures for all-cause mortality in older patients with non-small cell lung cancer
Minh-Thao Tu, Thi-Ngoc Tran, Hoejun Kwon, Yoon-Jung Choi, Youngjoo Lee, Hyunsoon Cho
Journal of Geriatric Oncology.2025; 16(1): 102130. CrossRef
Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel
Fuyumi Nishihara-Kato, Hisao Imai, Takeshi Tsuda, Satoshi Wasamoto, Yoshiaki Nagai, Takayuki Kishikawa, Yosuke Miura, Akihiro Ono, Yutaka Yamada, Ken Masubuchi, Takashi Osaki, Junichi Nakagawa, Yukihiro Umeda, Hiroyuki Minemura, Yuki Kozu, Hirokazu Tanigu
Oncology.2024; 102(1): 30. CrossRef
Diagnostic challenge and survival analysis of pulmonary oligometastases and primary lung cancer in breast cancer patients
Siyao Mai, Haiqing Liu, Hong Zeng, Ziliang Cheng, Jingwen Huang, Guangzi Shi, Yong Li, Zhuo Wu
Thoracic Cancer.2024; 15(12): 1017. CrossRef
Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study
Jiyun Lee, Hee Kyung Ahn, Sang‐We Kim, Ji‐Youn Han, Sung Sook Lee, Hyung Soon Park, Hyun Woo Lee, Joo‐Hang Kim, Eunhan Cho, Reto Huggenberger, Byoung Chul Cho
Cancer Medicine.2024;[Epub] CrossRef
Sex differences in prognosis factors in patients with lung cancer: A nationwide retrospective cohort study in Korea
Youn Huh, Yeo Ju Sohn, Hae-Rim Kim, Hyejin Chun, Hwa Jung Kim, Ki Young Son, Dong Keon Yon
PLOS ONE.2024; 19(5): e0300389. CrossRef
Glycemic status, insulin resistance, and mortality from lung cancer among individuals with and without diabetes
In Young Cho, Yoosoo Chang, Eunju Sung, Boyoung Park, Jae-Heon Kang, Hocheol Shin, Sarah H. Wild, Christopher D. Byrne, Seungho Ryu
Cancer & Metabolism.2024;[Epub] CrossRef
Mitochondrial Dynamics in Non-Small Cell Lung Cancer
Agata Dutkowska, Daria Domańska-Senderowska, Karolina H. Czarnecka-Chrebelska, Ewa Pikus, Aleksandra Zielińska, Laura Biskup, Agata Kołodziejska, Paulina Madura, Maria Możdżan, Urszula Załuska, Edward Zheng, Eliza Adamczyk, Konrad Kędzia, Szymon Wcisło, M
Cancers.2024; 16(16): 2823. CrossRef
Gender‐specific outcomes of low‐dose computed tomography screening for lung cancer detection: A retrospective study in Chinese never‐smoker population
Huihong Wang, Jicheng Xie, Yahong Chen, Jiang Jin, Meixian Zhang, TaoHsin Tung, Youzu Xu
Cancer Medicine.2024;[Epub] CrossRef
Survival of lung cancer patients according to screening eligibility using Korean Lung Cancer Registry 2014–2016
Sangwon Lee, Eun Hye Park, Bo Yun Jang, Ye Ji Kang, Kyu-Won Jung, Hyo Soung Cha, Kui Son Choi
Scientific Reports.2024;[Epub] CrossRef
Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015
Da Som Jeon, Ho Cheol Kim, Se Hee Kim, Tae-Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang-Gun Suh, Changhoon Song, Jin Seok Ahn, Jeong Eun Lee, Jeong Uk Lim, Jae Hyun Jeon, Kyu-Won Jung, Chi Young Jung, Jeong Su Cho, Yoo-Duk Choi, Seung
Cancer Research and Treatment.2023; 55(1): 103. CrossRef
Endobronchial ultrasound‐guided re‐biopsy of non–small cell lung cancer with acquired resistance after EGFR tyrosine kinase inhibitor treatment
Kyung Soo Hong, Jinmo Cho, Jong Geol Jang, Min Hye Jang, June Hong Ahn
Thoracic Cancer.2023; 14(4): 363. CrossRef
Stratifying non-small cell lung cancer patients using an inverse of the treatment decision rules: validation using electronic health records with application to an administrative database
Min-Hyung Kim, Sojung Park, Yu Rang Park, Wonjun Ji, Seul-Gi Kim, Minji Choo, Seung-Sik Hwang, Jae Cheol Lee, Hyeong Ryul Kim, Chang-Min Choi
BMC Medical Informatics and Decision Making.2023;[Epub] CrossRef
Regional lymph node recurrence after stereotactic body radiation therapy for lung cancer: Patterns of recurrence, treatment approaches, and clinical outcomes (KROG 21-09)
Tae Hoon Lee, Hyunju Shin, Yong Chan Ahn, Min Kyu Kang, Changhoon Song, Woo Chul Kim, Sung Ho Moon, Jin Hee Kim, Jaeho Cho, Hae Jin Park, Heui Kwan Lee, Byoung Hyuck Kim, Hak Jae Kim
Radiotherapy and Oncology.2023; 183: 109572. CrossRef
A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer
Cheol-Kyu Park, Nakyung Jeon, Hwa-Kyung Park, Hyung-Joo Oh, Young-Chul Kim, Ha-Lim Jeon, Yong-Hyub Kim, Sung-Ja Ahn, In-Jae Oh
Cancers.2023; 15(5): 1606. CrossRef
All-round counterattack to conquer lung cancer
Seung Hun Jang
Journal of the Korean Medical Association.2023; 66(3): 154. CrossRef
Efficacy of Prophylactic Cranial Irradiation According to the Risk of Extracranial Recurrence in Limited-Stage Small Cell Lung Cancer
Tae Hoon Lee, Joo-Hyun Chung, Hong-Gyun Wu, Suzy Kim, Joo Ho Lee, Bhumsuk Keam, Jin-Soo Kim, Ki Hwan Kim, Byoung Hyuck Kim, Hak Jae Kim
Cancer Research and Treatment.2023; 55(3): 875. CrossRef
Lung Cancer Screening in Asia: An Expert Consensus Report
David Chi-Leung Lam, Chong-Kin Liam, Sita Andarini, Samina Park, Daniel S.W. Tan, Navneet Singh, Seung Hun Jang, Varut Vardhanabhuti, Antonio B. Ramos, Tomio Nakayama, Nguyen Viet Nhung, Kazuto Ashizawa, Yeun-Chung Chang, Jamsak Tscheikuna, Cong Cung Van,
Journal of Thoracic Oncology.2023; 18(10): 1303. CrossRef
New insights into the biology and development of lung cancer in never smokers—implications for early detection and treatment
Peiyao Wang, Sophie Sun, Stephen Lam, William W. Lockwood
Journal of Translational Medicine.2023;[Epub] CrossRef
Sublobar Resection versus Stereotactic Body Radiation Therapy for Clinical Stage I Non–Small Cell Lung Cancer: A Study Using Data from the Korean Nationwide Lung Cancer Registry
Jeonghee Yun, Jong Ho Cho, Tae Hee Hong, Kyungmi Yang, Yong Chan Ahn, Hong Kwan Kim
Cancer Research and Treatment.2023; 55(4): 1171. CrossRef
Synthetic Tabular Data Based on Generative Adversarial Networks in Health Care: Generation and Validation Using the Divide-and-Conquer Strategy
Ha Ye Jin Kang, Erdenebileg Batbaatar, Dong-Woo Choi, Kui Son Choi, Minsam Ko, Kwang Sun Ryu
JMIR Medical Informatics.2023; 11: e47859. CrossRef
Long-term Survival According to N Stage Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Non-small Cell Lung Cancer
Bin Hwangbo, Eun Young Park, Bumhee Yang, Geon Kook Lee, Tae Sung Kim, Hyae Young Kim, Moon Soo Kim, Jong Mog Lee
Chest.2022; 161(5): 1382. CrossRef
Survival impact of prophylactic cranial irradiation in small-cell lung cancer in the modern era of magnetic resonance imaging staging
Yu Jin Lim, Changhoon Song, Hak Jae Kim
Radiation Oncology.2022;[Epub] CrossRef
Lung Cancer Screening with Low-Dose Chest Computed Tomography
Yeon Wook Kim
The Korean Journal of Medicine.2022; 97(1): 42. CrossRef
Association between clinical outcomes and local treatment in stage IV non‐small cell lung cancer patients with single extrathoracic metastasis
Jeong Uk Lim, Hye Seon Kang, Ah Young Shin, Chang Dong Yeo, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim
Thoracic Cancer.2022; 13(9): 1349. CrossRef
Analysis of thromboembolic events in patients with non-small cell lung cancer who received adjuvant chemotherapy: single-center real-world data
Tae-Hwan Kim, Yong Won Choi, Hyun Woo Lee, Seok Yun Kang, Heejun Son, Jin-Hyuk Choi, Mi Sun Ahn, Seung-Soo Sheen
Scientific Reports.2022;[Epub] CrossRef
Characteristics and clinical outcomes of patients with nonsmoking small cell lung cancer in Korea
Hye Seon Kang, Jung Uk Lim, Chang Dong Yeo, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim, Ho Cheol Kim, Chang Min Choi, Chi Young Jung, Deog Gon Cho, Jae Hyun Jeon, Jeong Eun Lee, Jin Seok Ahn, Yeongdae Kim, Yoo-Duk Choi, Yang-Gun Suh, Jung-Eun Kim, Youn
BMC Pulmonary Medicine.2022;[Epub] CrossRef
Sex differences in the characteristics and survival of patients with non‐small‐cell lung cancer: A retrospective analytical study based on real‐world clinical data of the Korean population
Da Som Jeon, Jin Woo Kim, Seul Gi Kim, Hyeong Ryul Kim, Si Yeol Song, Jae Cheol Lee, Wonjun Ji, Chang‐Min Choi, Ho Cheol Kim
Thoracic Cancer.2022; 13(18): 2584. CrossRef
Single-cell RNA sequencing analysis to explore immune cell heterogeneity and novel biomarkers for the prognosis of lung adenocarcinoma
Yong Xu, Yao Wang, Leilei Liang, Nan Song
Frontiers in Genetics.2022;[Epub] CrossRef
Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A
Cheol‐Kyu Park, Sung‐Yong Lee, Jae Cheol Lee, Chang‐Min Choi, Shin Yup Lee, Tae‐Won Jang, In‐Jae Oh, Young‐Chul Kim
Thoracic Cancer.2021; 12(4): 444. CrossRef
Active Treatment Improves Overall Survival in Extremely Older Non–Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study
Su Yeon Lee, Yoon-Ki Hong, Wonjun Ji, Jae Cheol Lee, Chang Min Choi
Cancer Research and Treatment.2021; 53(1): 104. CrossRef
A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim
Cancer Research and Treatment.2021; 53(1): 93. CrossRef
Prognostic significance of genetic variants in GLUT1 in stage III non‐small cell lung cancer treated with radiotherapy
Min Kyu Kang, Shin Yup Lee, Jin Eun Choi, Sun Ah Baek, Sook Kyung Do, Jeong Eun Lee, Jongmoo Park, Seung Soo Yoo, Sunha Choi, Kyung Min Shin, Ji Yun Jeong, Jae Yong Park
Thoracic Cancer.2021; 12(6): 874. CrossRef
Awareness and Use of Complementary and Alternative Medicine in Korean Lung Cancer Patients
Joon Young Choi, Wonjun Ji, Chang-Min Choi, Chaeuk Chung, Jae Myoung Noh, Cheol-Kyu Park, In-Jae Oh, Hong In Yoon, Hyeong Ryul Kim, Ho Young Kim, Chang Dong Yeo, Seung Hun Jang
Tuberculosis and Respiratory Diseases.2021; 84(2): 105. CrossRef
Recent Trends of Lung Cancer in Korea
Jae Guk Lee, Ho Cheol Kim, Chang-Min Choi
Tuberculosis and Respiratory Diseases.2021; 84(2): 89. CrossRef
Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
Hayoung Choi, Jae‐Kyeong Lee, Hyung‐Joo Oh, Min‐Seok Kim, Bo Gun Kho, Cheol Kyu Park, In‐Jae Oh, Young‐Chul Kim
Thoracic Cancer.2021; 12(10): 1598. CrossRef
Time‐varying effect of sex on prognosis of lung adenocarcinoma surgical patients in China
Zezhou Wang, Miao Mo, Changming Zhou, Xiaoshuang Feng, Jie Shen, Ting Ye, Yang Zhang, Hong Hu, Haiquan Chen, Ying Zheng
Thoracic Cancer.2021; 12(11): 1699. CrossRef
Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
Journal of Pathology and Translational Medicine.2021; 55(3): 181. CrossRef
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
Fernando Franco, Enric Carcereny, Maria Guirado, Ana L. Ortega, Rafael López-Castro, Delvys Rodríguez-Abreu, Rosario García-Campelo, Edel del Barco, Oscar Juan, Francisco Aparisi, Jose L. González-Larriba, Manuel Domine, Jose M. Trigo, Manuel Cobo, Sara C
PLOS ONE.2021; 16(6): e0251761. CrossRef
Survival Prediction of Lung Cancer Using Small-Size Clinical Data with a Multiple Task Variational Autoencoder
Thanh-Hung Vo, Guee-Sang Lee, Hyung-Jeong Yang, In-Jae Oh, Soo-Hyung Kim, Sae-Ryung Kang
Electronics.2021; 10(12): 1396. CrossRef
Impact of coexistent preserved ratio impaired spirometry on the survival of patients with lung cancer: Analysis of data from the Korean Association for Lung Cancer Registry
I. Re Heo, Ho Cheol Kim, Seung Jun Lee, Jung‐Wan Yoo, Sunmi Ju, Yi Yeong Jeong, Jong Deog Lee, Yu Ji Cho, Jong Hwan Jeong, Manbong Heo, Seung Woo Jung, Tae Hoon Kim
Thoracic Cancer.2021; 12(18): 2478. CrossRef
Lung Cancer in Korea
Sehhoon Park, Chang-Min Choi, Seung-Sik Hwang, Yoon-La Choi, Hyae Young Kim, Young-Chul Kim, Young Tae Kim, Ho Yun Lee, Si Yeol Song, Myung-Ju Ahn
Journal of Thoracic Oncology.2021; 16(12): 1988. CrossRef
Multiple genome pattern analysis and signature gene identification for the Caucasian lung adenocarcinoma patients with different tobacco exposure patterns
Yan-mei Dong, Li-da Qin, Yi-fan Tong, Qi-en He, Ling Wang, Kai Song
PeerJ.2020; 8: e8349. CrossRef
Efficacy of immune checkpoint inhibitors according to PD‐L1 tumor proportion scores in non‐small cell lung cancer
Seongho Park, Yoo‐Duk Choi, Jieun Kim, Bo‐Gun Kho, Cheol‐Kyu Park, In‐Jae Oh, Young‐Chul Kim
Thoracic Cancer.2020; 11(2): 408. CrossRef
Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing
Eunhyang Park, Hyo Sup Shim
Cancer Research and Treatment.2020; 52(2): 543. CrossRef
A New TTZ Feature Extracting Algorithm to Decipher Tobacco Related Mutation Signature Genes for the Personalized Lung Adenocarcinoma Treatment
Qien He, Zhewei Qiu, Yifan Tong, Kai Song
IEEE Access.2020; 8: 89031. CrossRef
Épidémiologie des cancers du poumon en France : les tendances actuelles
E. Giroux Leprieur, A. Vergnenègre, J. Trédaniel
Revue des Maladies Respiratoires Actualités.2020; 12(2): 2S6. CrossRef
Low-dose chest computed tomographic screening and invasive diagnosis of pulmonary nodules for lung cancer in never-smokers
Yeon Wook Kim, Hye-Rin Kang, Byoung Soo Kwon, Sung Yoon Lim, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Kyung Won Lee, Jae Ho Lee, Choon-Taek Lee
European Respiratory Journal.2020; 56(5): 2000177. CrossRef
Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors
Ji Soo Park, Beodeul Kang, Yehyun Park, Soo Jung Park, Jae Hee Cheon, Minkyu Jung, Seung Hoon Beom, Sang Joon Shin, Hyuk Hur, Byung Soh Min, Seung Hyuk Baik, Kang Young Lee, Joong Bae Ahn, Nam Kyu Kim, Tae Il Kim
Journal of Cancer Prevention.2019; 24(1): 48. CrossRef
Épidémiologie des cancers du poumon en France: les tendances actuelles
A. Vergnenègre, J. Trédaniel, L. Bigay-Gamé, O. Bylicki, J-C. Pairon, T. Urban, M. Colonna
Revue des Maladies Respiratoires Actualités.2019; 11(3): 169. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014

Cancer Res Treat. 2019;51(4):1400-1410. Published online February 25, 2019

DOI: https://doi.org/10.4143/crt.2018.704

XML Download

Figure

Related articles

Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015

Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014

Fig. 1. Overall survival in patients with non-small cell lung cancer, according to sex (A) and clinical stage (B). Overall survival in patients with small cell lung cancer, according to sex (C) and clinical stage (D).

Fig. 2. Overall survival in patients with stage IV adenocarcinoma, according to sex (A) and epidermal growth factor receptor (EGFR) mutation (B).

Fig. 1.

Fig. 2.

Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014

	Survey population	Sample	p-value
No. of patients	21,960	2,621
Male sex	15,500 (70.6)	1,876 (71.6)	0.291
Age category (yr) (total patients)
< 40	245 (1.1)	29 (1.1)	0.524
40-50	926 (4.2)	121 (4.6)
50-60	3,416 (15.6)	424 (16.2)
60-70	5,996 (27.3)	734 (28.0)
≥ 70	11,377 (51.8)	1,313 (50.1)
Age category (yr) (male patient)
< 40	119 (0.8)	15 (0.8)	0.563
40-50	511 (3.3)	72 (3.8)
50-60	2,204 (14.2)	283 (15.1)
60-70	4,487 (29.0)	542 (28.9)
≥ 70	8,179 (52.8)	964 (51.4)
Age category (yr) (female patient)
< 40	126 (2.0)	14 (1.9)	0.617
40-50	415 (6.4)	49 (6.6)
50-60	1,212 (18.8)	141 (18.9)
60-70	1,509 (23.4)	192 (25.8)
≥ 70	3,198 (49.5)	349 (46.9)

	Total	Men	Women	p-value
No. of patients	2,621	1,876 (71.6)	745 (28.4)
Age (yr)	70 (61-76)	70 (62-76)	68 (58-75)	0.002
Ever-smoker (n=2,580)	1,641 (63.6)	1,549 (84.0)	92 (12.5)	< 0.001
BMI (kg/m²)	22.9±3.6	22.7±3.5	23.6±3.7	< 0.001
Symptoms
Asymptomatic	360 (13.7)	239 (12.7)	121 (16.2)	0.019
Cough	922 (35.2)	689 (36.7)	233 (31.3)	0.008
Sputum	564 (21.5)	446 (23.8)	118 (15.8)	< 0.001
Dyspnea	534 (20.4)	380 (20.3)	154 (20.7)	0.812
Hoarseness	46 (1.8)	40 (2.1)	6 (0.8)	0.020
Hemoptysis	157 (6.0)	139 (7.4)	18 (2.4)	< 0.001
Weight loss	168 (6.4)	136 (7.2)	32 (4.3)	0.005
Pain	512 (19.5)	369 (19.7)	143 (19.2)	0.782
Histopathology
Adenocarcinoma	1,269 (48.4)	712 (38.0)	557 (74.8)	< 0.001
Squamous cell carcinoma	654 (25.0)	597 (31.8)	57 (7.7)	< 0.001
Small cell carcinoma	356 (13.6)	303 (16.2)	53 (7.1)	< 0.001
Others	354 (13.5)	272 (14.5)	82 (11.0)	0.019
Performance status (n=1,873)
0-1	1,756 (93.8)	1,235 (93.2)	521 (95.1)	0.129
2-4	117 (6.2)	90 (6.8)	27 (4.9)
Clinical stage of NSCLC (n=2,234)
I	634 (28.4)	369 (23.8)	265 (38.7)	< 0.001
II	190 (8.5)	146 (9.4)	44 (6.4)
III	405 (18.1)	331 (21.4)	74 (10.8)
IV	1,005 (45.0)	703 (45.4)	302 (44.1)
Initial treatment of NSCLC (n=2,265)
Surgery	851 (37.6)	536 (34.1)	315 (45.5)	< 0.001
Surgery only	563 (66.2)	343 (64.0)	220 (69.8)
Surgery and adjuvant therapy	288 (33.8)	193 (36.0)	95 (30.2)
RT only	188 (8.3)	152 (9.7)	36 (5.2)	< 0.001
CCRT	96 (4.2)	78 (5.0)	18 (2.6)	0.010
Chemotherapy	657 (29.0)	456 (29.0)	201 (29.0)	0.978
Best supportive care	289 (12.8)	222 (14.1)	67 (9.7)	0.004
Unknown	184 (8.1)	129 (8.2)	55 (7.9)	0.839
Clinical stage of SCLC (n=350)
Limited stage	128 (36.6)	109 (36.7)	19 (35.8)	0.906
Extensive stage	222 (63.4)	188 (63.3)	34 (64.2)
Initial treatment of SCLC (n=356)
Surgery	10 (2.8)	9 (3.0)	1 (1.9)	1.000
RT only	17 (4.8)	14 (4.6)	3 (5.7)	0.727
CCRT	55 (15.4)	46 (15.2)	9 (17.0)	0.738
Chemotherapy	213 (59.8)	186 (61.4)	27 (50.9)	0.153
Best supportive care	46 (12.9)	36 (11.9)	10 (18.9)	0.162
Unknown	15 (4.2)	12 (4.0)	3 (5.7)	0.570

	Total	Ever-smoker	Never-smoker	p-value
No. of patients	2,580	1,641 (63.6)	939 (36.4)
Male sex	1,845 (71.5)	1,549 (94.4)	296 (31.5)	< 0.001
Age (yr)	69 (61-76)	70 (62-76)	69 (59-76)	0.055
BMI (kg/m²)	22.9±3.5	22.6±3.5	23.4±3.6	< 0.001
Symptoms
Asymptomatic	357 (13.8)	200 (12.2)	157 (16.7)	0.001
Cough	913 (35.4)	630 (38.4)	283 (30.1)	< 0.001
Sputum	557 (21.6)	407 (24.8)	150 (16.0)	< 0.001
Dyspnea	527 (20.4)	358 (21.8)	169 (18.0)	0.021
Hoarseness	46 (1.8)	37 (2.3)	9 (1.0)	0.017
Hemoptysis	156 (6.0)	129 (7.9)	27 (2.9)	< 0.001
Weight loss	167 (6.5)	128 (7.8)	39 (4.2)	< 0.001
Pain	508 (19.7)	326 (19.9)	182 (19.4)	0.766
Performance status (n=1,857)
0-1	1,743 (93.9)	1,091 (93.0)	652 (95.3)	0.045
2-4	114 (6.1)	82 (7.0)	32 (4.7)
Clinical stage of NSCLC (n=2,201)
I	631 (28.7)	311 (23.3)	320 (36.8)	< 0.001
II	187 (8.5)	127 (9.5)	60 (6.9)
III	399 (18.1)	305 (22.9)	94 (10.8)
IV	984 (44.7)	589 (44.2)	395 (45.5)
Clinical stage of SCLC (n=344)
Limited stage	126 (36.6)	112 (39.2)	14 (24.1)	0.030
Extensive stage	218 (63.4)	174 (60.8)	44 (75.9)

	Ever-smoker (≥ 30 pack years, n=1,116, 43.3%)			Ever-smoker (< 30 pack years, n=525, 20.3%)			Never-smoker (n=939, 36.4%)
	Men	Women	p-value	Men	Women	p-value	Men	Women	p-value
No. of patients	1,085 (97.2)	31 (2.8)		464 (88.4)	61 (11.6)		296 (31.5)	643 (68.5)
Age (yr)	70 (63-75)	71 (64-82)	0.378	70 (59-76)	68 (58-78)	0.817	71 (63-77)	68 (58-75)	0.003
Age category (yr)
0-50	19 (1.8)	2 (6.5)	0.027	48 (10.3)	6 (9.8)	0.816	20 (6.8)	55 (8.6)	0.086
50-60	169 (15.6)	3 (9.7)		74 (15.9)	12 (19.7)		38 (12.8)	125 (19.4)
60-70	342 (31.5)	10 (32.3)		110 (23.7)	13 (21.3)		82 (27.7)	168 (26.1)
70-80	431 (39.7)	8 (25.8)		167 (36.0)	19 (31.1)		115 (38.9)	221 (34.4)
≥ 80	124 (11.4)	8 (25.8)		65 (14.0)	11 (18.0)		41 (13.9)	74 (11.5)
Performance status
0-1	727 (67.0)	18 (58.1)	0.106	302 (65.1)	44 (72.1)	0.356	194 (65.5)	464 (71.2)	0.172
2-4	51 (4.7)	4 (12.9)		23 (5.0)	4 (6.6)		13 (4.4)	19 (3.0)
Unknown	306 (28.3)	9 (29.0)		139 (30.0)	13 (21.3)		89 (30.1)	166 (25.8)
Histology
Adenocarcinoma	329 (30.3)	7 (22.6)	0.349	204 (44.4)	29 (47.5)	0.109	166 (56.1)	514 (79.9)	< 0.001
Squamous cell carcinoma	387 (35.7)	11 (35.5)		134 (28.9)	16 (26.2)		64 (21.6)	27 (4.2)
Small cell lung cancer	216 (19.9)	10 (32.3)		54 (11.6)	12 (19.7)		28 (9.5)	30 (4.7)
Others	153 (14.1)	3 (9.7)		72 (15.5)	4 (6.6)		38 (12.8)	72 (11.2)
NSCLC stage
I	189 (21.7)	7 (33.3)	0.752	103 (25.1)	12 (24.5)	0.698	75 (28.0)	245 (40.0)	0.006
II	98 (11.3)	2 (9.5)		23 (5.6)	4 (8.2)		22 (8.2)	38 (6.2)
III	213 (24.5)	4 (19.0)		76 (18.5)	12 (24.5)		36 (13.4)	58 (9.5)
IV	356 (41.0)	8 (38.1)		204 (49.8)	21 (42.9)		129 (48.1)	266 (43.4)
Unknown	13 (1.5)	0		4 (1.0)	0		6 (2.2)	6 (1.0)
SCLC
Limited	87 (40.3)	4 (40.0)	0.908	14 (25.9)	7 (58.3)	0.085	7 (25.0)	7 (23.3)	0.882
Extensive	125 (57.9)	6 (60.0)		38 (70.4)	5 (41.7)		21 (75.0)	23 (76.7)
Unknown	4 (1.9)	0		2 (3.7)	0		0	0

	Univariate analysis			Multivariate analysis
	Hazard ratio	95% CI	p-value	Hazard ratio	95% CI	p-value
Age	1.036	1.028-1.043	< 0.001	1.020	1.012-1.028	< 0.001
Male sex	2.112	1.788-2.494	< 0.001	1.704	1.326-2.182	< 0.001
Ever-smoker	1.772	1.572-2.056	< 0.001	1.038	0.829-1.298	0.747
BMI	0.895	0.876-0.915	< 0.001	0.954	0.930-0.979	< 0.001
Performance status
0-1 (ref)	1.000			1.000
2-4	3.166	2.453-4.085	< 0.001	1.410	1.012-1.964	0.042
Clinical stage
I (ref)	1.000			1.000
II	3.539	2.406-5.203	< 0.001	2.494	1.602-3.881	< 0.001
III	7.946	5.883-10.734	< 0.001	4.141	2.854-6.007	< 0.001
IV	13.634	10.330-17.994	< 0.001	6.972	4.861-9.999	< 0.001
Histology
Adenocarcinoma (ref)	1.000			1.000
Squamous cell carcinoma	1.833	1.575-2.133	< 0.001	1.187	0.994-1.430	0.053
Treatment
Surgery (ref)	1.000			1.000
Non-surgical treatment	6.516	5.364-7.916	< 0.001	2.214	1.711-2.864	< 0.001
Best supportive care	15.733	12.044-20.552	< 0.001	4.954	3.495-7.021	< 0.001

	Univariate analysis			Multivariate analysis
	Hazard ratio	95% CI	p-value	Hazard ratio	95% CI	p-value
Age	1.042	1.028-1.057	< 0.001	1.036	1.019-1.054	< 0.001
Male sex	1.045	0.754-1.448	0.793
Ever-smoker	0.705	0.518-0.959	0.026	0.867	0.588-1.280	0.473
BMI	0.910	0.877-0.945	< 0.001	0.938	0.901-0.977	0.002
Performance status
0-1 (ref)	1.000			1.000
2-4	3.106	1.947-4.955	< 0.001	2.436	1.379-4.305	0.002
Clinical stage
Limited (ref)	1.000			1.000
Extensive	2.262	1.762-2.903	< 0.001	2.331	1.719-3.160	< 0.001
Treatment
Anti-cancer treatment (ref)	1.000			1.000
Best supportive care	4.925	3.514-6.904	< 0.001	2.173	1.320-3.576	0.002

	Total	Men	Women	p-value
No. of patients	571	339 (59.4)	232 (40.6)
Age (yr)	68 (58-76)	67 (58-74)	70 (57-76)	0.168
Ever-smoker(n=561)	272 (48.5)	255 (76.3)	17 (7.5)	< 0.001
BMI (kg/m²)	22.6±3.3	22.4±3.3	22.9±3.3	0.060
Performance status (n=414)
0-1	386 (93.2)	227 (92.3)	159 (94.6)	0.346
2-4	28 (6.8)	19 (7.7)	9 (5.4)
EGFR mutation status (n=496)
Positive	182 (36.8)	77 (26.6)	105 (51.2)	< 0.001
Negative	313 (63.2)	213 (73.4)	100 (48.8)
EGFR target agent usage
Yes	122 (67.0)	48 (62.3)	74 (70.5)	0.249
No	60 (33.0)	29 (37.7)	31 (29.5)
ALK translocation status (n=109)
Positive	15 (13.8)	7 (12.1)	8 (15.7)	0.584
Negative	94 (86.2)	51 (87.9)	43 (84.3)
ALK target agent usage
Yes	7 (46.7)	1 (14.3)	6 (75.0)	0.041
No	8 (53.3)	6 (85.7)	2 (25.0)

Table 1. Comparison of sex and age category between survey population and sample

Values are presented as number (%).

Table 2. Baseline characteristics of study patients in the year 2014

Table 3. Comparison of characteristics between ever-smoker and never-smoker participants

Values are presented as number (%), median (interquartile range), or mean±standard deviation. BMI, body mass index; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.

Table 4. Clinicopathologic characteristics of patients according to smoking frequency, stratified by sex (total=2,580)

Values are presented as number (%) or median (interquartile range). NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.

Table 5. Risk factors for mortality in patients with NSCLC assessed by Cox proportional hazards model

NSCLC, non-small cell lung cancer; CI, confidence interval; BMI, body mass index.

Table 6. Risk factors for mortality in patients with small cell lung cancer assessed using Cox proportional hazards models

CI, confidence interval; BMI, body mass index.

Table 7. Characteristics of patients with stage IV adenocarcinoma

Values are presented as median (interquartile range), number (%), or mean±standard deviation. BMI, body mass index; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.